NovaBay Pharma (NBY) Misses Q1 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results
May 12, 2016 4:11 PM EDTCloses the first tranche of an $11.8 million private placement Affirms outlook to reach positive cash flow from operations by the end of 2016 First quarter 2016 sales reached $1.7 million and $2.3 million on a pro forma non-GAAP basis Recent highlights feature clinical validation that Avenova® reduces the bacteria that can cause blepharitis and the launch of a new marketing strategy Conference call begins today at 4:30 p.m. Eastern time
EMERYVILLE, Calif.--(BUSINESS WIRE)--... More
